AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has completed a study focusing on the performance of its NeuCovix™ rapid test measuring the neutralizing levels of anti-COVID-19 antibodies.
NeuCovix™ accurately categorizes blood serum
The company compared the NeuCovix™ with the pseudovirus-based gold standard test. Results indicated that the NeuCovix™ test precisely categorized serum form COVID-19 patients that had strongly neutralized the SARS-CoV-2 as well as serum from those that had neutralized the virus poorly. Interestingly there was no cross-reaction with serum for the NeuCovix™ test for patients with seasonal respiratory infections that include seasonal coronavirus, which is an indication that the test has almost 100% specificity for SARS-CoV-2.
The current tests that use live viruses are expensive, time-consuming, and need highly trained personnel working in a tightly managed lab environment in measuring neutralizing antibodies. On the other hand, the NeuCovix™ test is cheap, portable, and quick point-of-care tests that determine the neutralizing antibody level in less than ten minutes. Considering the NeuCovix™ tests are in line with virus assay, it could prove to be an effective and affordable tool in monitoring huge numbers of subjects receiving vaccines for antibody neutralizing.
NeuCovix™ test is faster and less expensive
Also, NeuCovix™ can be used in measuring neutralizing antibodies levels in patients under that are receiving convalescent plasma or hyperimmune globulin to enable healthcare providers to determine the ideal neutralizing antibodies dosing that is in line with favorable results. John Huemoeller II, the CEO of AXIM® Biotech, stated that they were delighted with the preliminary test results showed by NeuCovix™. He added that the difference the tests deliver in time of money and time for vaccine developers and blood centers is huge.
AXIM® Biotech’s wholly-owned subsidiary, Sapphire Biotech’s Chief Scientific Officer Sergei Svarovusky, said that there is still work that needs to be done EUA. Sergei said that the 10-minute test has shown almost similar protective immune outcomes in samples of plasma from patients with high and low titers compared to the other time consuming and expensive lab tests.
3 Big Biotech Disruptors For 2021
Post Views: 21,239
Post Views: 69,489 CBD market growth over the next ten years will outpace marijuana growth by more than 30-to-one By...
Stem Holdings Inc (OTCMKTS:STMH) Reports A Growth Of 960% In Q3 2020: Unveils TJGardens Branded Tinctures
Post Views: 1,393 Stem Holdings Inc (OTCMKTS:STMH) posted an increase of 960% YoY to $6.7 million in Q3 2020. It...
Indiva Ltd (OTCMKTS:NDVAF) Signs Three Provincial Agreements: Expands Distribution Network To Eight Provinces: Reports A Robust Growth Of 1273.7% In Q2 2020 Revenues
Post Views: 1,315 Indiva Ltd (OTCMKTS:NDVAF) posted a robust growth of 1273.7% YoY to CAD 2.826 million in revenues in...
4Front Ventures Corp (OTCMKTS:FFNTF) Receives Approval From CCC For Mission Dispensary and Cultivation Facilities In Worcester: Will Commence Adult-Use Cannabis Sales
Post Views: 1,325 CCC (Cannabis Control Commission) in Massachusetts approved cultivation and processing facilities and Mission Dispensary of 4Front Ventures...
Pure Sunfarms, A Joint Venture Of Village Farms International Inc (NASDAQ:VFF), Ships Bottled Oil Products TO British Columbia
Post Views: 1,426 Pure Sunfarms, which is a Village Farms International Inc (NASDAQ:VFF) JV, commenced shipment of Cannabis 2.0 products...